

Manjunath P Pai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1014474/publications.pdf>

Version: 2024-02-01

160
papers

6,433
citations

101384

36
h-index

74018

75
g-index

164
all docs

164
docs citations

164
times ranked

6195
citing authors

#	ARTICLE	IF	CITATIONS
1	Medication Use Among U.S. Adults After Bariatric Surgery: A Population-Based Analysis of NHANES 2015–2018. <i>Diabetes Care</i> , 2022, 45, e54-e55.	4.3	1
2	Muscle Mass Affects Paclitaxel Systemic Exposure and May Inform Personalized Paclitaxel Dosing. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	2
3	Comparison of Race-Based and Non-Race-Based Equations for Kidney Function Estimation in Critically Ill Thai Patients for Vancomycin Dosing. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1215-1226.	1.0	1
4	Predicting CNS penetration of precision medicine therapies in oncology: A comparison of the CNS TAP tool and the BOILED-Egg computational model.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2062-2062.	0.8	0
5	Antimicrobial Dosing in Specific Populations and Novel Clinical Methodologies: Obesity. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 942-951.	2.3	8
6	Administration of valproic acid in clinically approved dose improves neurologic recovery and decreases brain lesion size in swine subjected to hemorrhagic shock and traumatic brain injury. <i>Journal of Trauma and Acute Care Surgery</i> , 2021, 90, 346-352.	1.1	5
7	A single dose of valproic acid improves neurologic recovery and decreases brain lesion size in swine subjected to an isolated traumatic brain injury. <i>Journal of Trauma and Acute Care Surgery</i> , 2021, 91, 867-871.	1.1	3
8	Validity of 2020 vancomycin consensus recommendations and further guidance for practical application. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 1364-1367.	0.5	7
9	Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. <i>Leukemia and Lymphoma</i> , 2021, 62, 1990-1994.	0.6	9
10	Validation of intraosseous delivery of valproic acid in a swine model of polytrauma. <i>Trauma Surgery and Acute Care Open</i> , 2021, 6, e000683.	0.8	0
11	High-Dose Micafungin in Neonates and Young Infants with Invasive Candidiasis: Results of a Phase 2 Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	11
12	Antimicrobial Dosing in Specific Populations and Novel Clinical Methodologies: Kidney Function. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 952-957.	2.3	6
13	Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	10
14	Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 555-562.	1.1	15
15	Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial. <i>Respiratory Medicine</i> , 2021, 184, 106442.	1.3	6
16	Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. <i>Biomaterials</i> , 2021, 275, 120910.	5.7	37
17	Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0079221.	1.4	5
18	Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1315-1322.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1025-1031.	1.3	18
20	Translation of Pharmacodynamic Biomarkers of Antibiotic Efficacy in Specific Populations to Optimize Doses. <i>Antibiotics</i> , 2021, 10, 1368.	1.5	0
21	Application of an innovative high-throughput liquid chromatography-tandem mass spectrometry method for simultaneous analysis of 18 hazardous drugs to rule out accidental acute chemotherapy exposures in health care workers. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 794-802.	0.5	12
22	Development of a sensitive LC-MS/MS method for quantification of linezolid and its primary metabolites in human serum. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 178, 112968.	1.4	11
23	Mechanistic Deconvolution of Oral Absorption Model with Dynamic Gastrointestinal Fluid to Predict Regional Rate and Extent of GI Drug Dissolution. <i>AAPS Journal</i> , 2020, 22, 3.	2.2	6
24	Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics. <i>Clinical Pharmacokinetics</i> , 2020, 59, 409-425.	1.6	22
25	Using L-Carnitine as a Pharmacologic Probe of the Interpatient and Metabolic Variability of Sepsis. <i>Pharmacotherapy</i> , 2020, 40, 913-923.	1.2	10
26	Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Clinical Infectious Diseases</i> , 2020, 71, 1361-1364.	2.9	142
27	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 281-284.	0.6	33
28	Modeling Kinetic Glomerular Filtration Rate in Adults with Stable and Unstable Kidney Function: Vancomycin as the Motivating Example. <i>Pharmacotherapy</i> , 2020, 40, 872-879.	1.2	6
29	Questions on Vancomycin Dosing. <i>Clinical Infectious Diseases</i> , 2020, 73, e1777-e1778.	2.9	1
30	Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts. <i>Clinical Cancer Research</i> , 2020, 26, 5246-5257.	3.2	12
31	Maintenance Immunosuppression in Solid Organ Transplantation: Integrating Novel Pharmacodynamic Biomarkers to Inform Calcineurin Inhibitor Dose Selection. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1317-1334.	1.6	1
32	Life on the battlefield: Valproic acid for combat applications. <i>Journal of Trauma and Acute Care Surgery</i> , 2020, 89, S69-S76.	1.1	9
33	Use of Oral Tetracyclines in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia: A Literature Review on the Often-Overlooked Antibiotic Class. <i>Antibiotics</i> , 2020, 9, 905.	1.5	13
34	Dose optimization of early high-dose valproic acid for neuroprotection in a swine cardiac arrest model. <i>Resuscitation Plus</i> , 2020, 1-2, 100007.	0.6	1
35	Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus</i> infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 835-864.	0.5	640
36	Comparison of Body Size, Morphometrics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma. <i>Pharmacotherapy</i> , 2020, 40, 308-319.	1.2	12

#	ARTICLE	IF	CITATIONS
37	Small molecule activation of metabolic enzyme pyruvate kinase muscle isozyme 2, PKM2, circumvents photoreceptor apoptosis. <i>Scientific Reports</i> , 2020, 10, 2990.	1.6	20
38	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2020, 40, 363-367.	1.2	56
39	Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	15
40	Valproic acid treatment rescues injured tissues after traumatic brain injury. <i>Journal of Trauma and Acute Care Surgery</i> , 2020, 89, 1156-1165.	1.1	8
41	Everolimus improves the efficacy of dasatinib in PDGFR \pm -driven glioma. <i>Journal of Clinical Investigation</i> , 2020, 130, 5313-5325.	3.9	41
42	An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen. <i>ELife</i> , 2020, 9, .	2.8	15
43	Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. <i>Clinical Infectious Diseases</i> , 2019, 69, S16-S22.	2.9	34
44	Vancomycin volume of distribution estimation in adults with class III obesity. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 2013-2018.	0.5	3
45	HGG-03. EVEROLIMUS TREATMENT IMPROVES THE CNS PENETRATION AND EFFICACY OF DASATINIB IN THE TREATMENT OF PDGFRA-DRIVEN PEDIATRIC HIGH-GRADE GLIOMA AND DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, ii87-ii87.	0.6	0
46	Repurposing azithromycin for neonatal neuroprotection. <i>Pediatric Research</i> , 2019, 86, 444-451.	1.1	27
47	Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	63
48	Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel. <i>Molecular Pharmaceutics</i> , 2019, 16, 2385-2393.	2.3	7
49	Insights Into the Evolution of <i>Staphylococcus aureus</i> Daptomycin Resistance From an in vitro Bioreactor Model. <i>Frontiers in Microbiology</i> , 2019, 10, 345.	1.5	8
50	Optimizing Estimated Glomerular Filtration Rate to Support Adult to Pediatric Pharmacokinetic Bridging Studies in Patients with Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1323-1332.	1.6	8
51	Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy. <i>Critical Care Medicine</i> , 2019, 47, e863-e871.	0.4	16
52	Dose optimization of valproic acid in a lethal model of traumatic brain injury, hemorrhage, and multiple trauma in swine. <i>Journal of Trauma and Acute Care Surgery</i> , 2019, 87, 1133-1139.	1.1	14
53	Estimating Renal Function in Drug Development: Time to Take the Fork in the Road. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 159-167.	1.0	23
54	Renal Dosing of Antibiotics: Are We Jumping the Gun?. <i>Clinical Infectious Diseases</i> , 2019, 68, 1596-1602.	2.9	85

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics and Pharmacodynamics of β -Lactamase Inhibitors. <i>Pharmacotherapy</i> , 2019, 39, 182-195.	1.2	41
56	Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 126-129.	1.3	2
57	The effect of everolimus on CNS penetration and efficacy of dasatinib in the treatment of <i>c-kit</i> -driven glioma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13508-e13508.	0.8	1
58	Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	5
59	Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 331-340.	1.5	13
60	Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	8
61	Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	65
62	Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. <i>Clinical Cancer Research</i> , 2018, 24, 3602-3610.	3.2	40
63	Survival in Patients with <i>Candida glabrata</i> Bloodstream Infection Is Associated with Fluconazole Dose. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	11
64	Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial. <i>Clinical Pharmacokinetics</i> , 2018, 57, 209-219.	1.6	42
65	Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. <i>Clinical Pharmacokinetics</i> , 2018, 57, 989-1000.	1.6	26
66	Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 111, 465-481.	1.9	22
67	1416. Piperacillin/Tazobactam Therapeutic Drug Monitoring: True Interpatient Variability or Compound Instability?. <i>Open Forum Infectious Diseases</i> , 2018, 5, S436-S437.	0.4	0
68	Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing. <i>Pharmacotherapy</i> , 2018, 38, 1229-1238.	1.2	59
69	Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans. <i>Clinical Pharmacology: Advances and Applications</i> , 2018, Volume 10, 165-174.	0.8	3
70	Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles. <i>Molecular Pharmaceutics</i> , 2018, 15, 4505-4516.	2.3	15
71	Dosing vancomycin in the super obese: less is more. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3081-3086.	1.3	40
72	Macrolides, Azalides, and Ketolides. , 2018, , 57-86.		0

#	ARTICLE	IF	CITATIONS
73	Validation of Heel Stick Microsampling To Optimize Micafungin Doses in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	6
74	In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 97, 17-23.	1.3	6
75	A Fixed versus Weight-Based Dosing Strategy of Daptomycin May Improve Safety in Obese Adults. <i>Pharmacotherapy</i> , 2018, 38, 981-985.	1.2	16
76	Characterization of genetic changes associated with daptomycin nonsusceptibility in <i>Staphylococcus aureus</i> . <i>PLoS ONE</i> , 2018, 13, e0198366.	1.1	24
77	Introduction to Drug-Drug Interactions. , 2018, , 1-13.		1
78	Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers Bias. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	16
79	<i>In Vivo</i> Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions. <i>Molecular Pharmaceutics</i> , 2017, 14, 4295-4304.	2.3	46
80	Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to <i>Pseudomonas aeruginosa</i> with MIC values between 4 and 32 mg/L. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2813-2816.	1.3	32
81	Relationships of Vancomycin Pharmacokinetics to Body Size and Composition Using a Novel Pharmacomorphomic Approach Based on Medical Imaging. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	6
82	Valproic acid decreases brain lesion size and improves neurologic recovery in swine subjected to traumatic brain injury, hemorrhagic shock, and polytrauma. <i>Journal of Trauma and Acute Care Surgery</i> , 2017, 83, 1066-1073.	1.1	48
83	Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate <i>Staphylococcus aureus</i> (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study. <i>BMC Infectious Diseases</i> , 2017, 17, 534.	1.3	7
84	Determination of Alternative Ceftolozane/Tazobactam (C/T) Dosing Regimens for Patients With Infections Due to <i>Pseudomonas aeruginosa</i> With High (C/T) MIC Values. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
85	Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4585-4589.	1.4	20
86	Insulin Glargine and Insulin Aspart Overdose With Pharmacokinetic Analysis. <i>AACE Clinical Case Reports</i> , 2016, 2, e122-e128.	0.4	4
87	Pharmacodynamics and Obesity. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 599-620.	0.1	0
88	High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7333-7339.	1.4	26
89	Anti-infective Dosing for Obese Adult Patients: A Focus on Newer Drugs to Treat Methicillin-resistant <i>Staphylococcus aureus</i> Acute Bacterial Skin and Skin Structure Infections. <i>Clinical Therapeutics</i> , 2016, 38, 2032-2044.	1.1	17
90	Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis. <i>Surgical Infections</i> , 2016, 17, 675-682.	0.7	1

#	ARTICLE	IF	CITATIONS
91	Individualized Vancomycin Dosing in Obese Patients: A Two-Sample Measurement Approach Improves Target Attainment. <i>Pharmacotherapy</i> , 2015, 35, 455-463.	1.2	41
92	Do Formulation Differences between the Reference Listed Drug and Generic Piperacillin-Tazobactam Impact Reconstitution?. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1767-1769.	1.4	1
93	Treatment of bacterial infections in obese adult patients: how to appropriately manage antimicrobial dosage. <i>Current Opinion in Pharmacology</i> , 2015, 24, 12-17.	1.7	13
94	Pharmacokinetics and Pharmacodynamics of Continuous Infusion Meropenem in Overweight, Obese, and Morbidly Obese Patients with Stable and Unstable Kidney Function: A Step Toward Dose Optimization for the Treatment of Severe Gram-Negative Bacterial Infections. <i>Clinical Pharmacokinetics</i> , 2015, 54, 933-941.	1.6	31
95	Optimizing the Initial Amikacin Dosage in Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7094-7096.	1.4	25
96	Pharmacokinetics of Ceftaroline in Normal Body Weight and Obese (Classes I, II, and III) Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3956-3965.	1.4	27
97	Pharmacokinetics and Pharmacodynamics of Anti-infective Agents. , 2015, , 252-262.e2.		3
98	Reply to Di Paolo et al. <i>Clinical Infectious Diseases</i> , 2014, 58, 1789-1790.	2.9	6
99	Simplified Equations Using Two Concentrations To Calculate Area under the Curve for Antimicrobials with Concentration-Dependent Pharmacodynamics: Daptomycin as a Motivating Example. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3162-3167.	1.4	36
100	Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 190-199.	1.3	29
101	Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMI ≥ 40 kg/m ²) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body Weight and Optimized by Therapeutic Drug Monitoring. <i>Clinical Pharmacokinetics</i> , 2014, 53, 753-762.	1.6	33
102	Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 176-179.	1.3	19
103	Relationship between Time to Clinical Response and Outcomes among Pneumonia Outcomes Research Team (PORT) Risk Class III and IV Hospitalized Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and Azithromycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3804-3813.	1.4	21
104	Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 178-187.	0.8	25
105	Innovative approaches to optimizing the delivery of vancomycin in individual patients. <i>Advanced Drug Delivery Reviews</i> , 2014, 77, 50-57.	6.6	215
106	617. <i>Critical Care Medicine</i> , 2014, 42, A1508.	0.4	0
107	Polymyxin B Dosing in Obese and Underweight Adults. <i>Clinical Infectious Diseases</i> , 2013, 57, 1785-1785.	2.9	12
108	Considerations for Higher Doses of Daptomycin in Critically Ill Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. <i>Clinical Infectious Diseases</i> , 2013, 57, 1568-1576.	2.9	118

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetics and Pharmacodynamics of Once-Daily Administration of Intravenous Tobramycin in Adult Patients with Cystic Fibrosis Hospitalized for an Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5175-5177.	1.4	11
110	Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects?. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 666-673.	1.3	31
111	Effects of Obesity and Sex on Antimicrobial Pharmacokinetics and Acute Kidney Injury: Validation of a Preclinical Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 716-722.	1.4	3
112	Comment on: Acute renal insufficiency during telavancin therapy in clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1300-1301.	1.3	7
113	Applications of Pharmacokinetic and Pharmacodynamic Principles to Optimize Drug Dosage Selection. , 2012, , 175-196.		0
114	The Influence of Body Size Descriptors on the Estimation of Kidney Function in Normal Weight, Overweight, Obese, and Morbidly Obese Adults. <i>Annals of Pharmacotherapy</i> , 2012, 46, 317-328.	0.9	36
115	The not so "ideal" body weight-based dosing of Integrilin in obesity. <i>American Heart Journal</i> , 2012, 163, e23.	1.2	1
116	Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese Adults. <i>Pharmacotherapy</i> , 2012, 32, 856-868.	1.2	134
117	The effects of obesity on drug pharmacokinetics in humans. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 697-706.	1.5	82
118	Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors That Influence Protein Binding. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4277-4282.	1.4	69
119	Vancomycin: We Can't Get There From Here. <i>Clinical Infectious Diseases</i> , 2011, 52, 969-974.	2.9	214
120	Simplified Estimation of Aminoglycoside Pharmacokinetics in Underweight and Obese Adult Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4006-4011.	1.4	72
121	Oseltamivir and Oseltamivir Carboxylate Pharmacokinetics in Obese Adults: Dose Modification for Weight Is Not Necessary. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5640-5645.	1.4	29
122	Steady-State Plasma Pharmacokinetics of Oral Voriconazole in Obese Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2601-2605.	1.4	41
123	Macrolides, Azalides, and Ketolides. , 2011, , 243-275.		1
124	Clinical Pharmacokinetics of Oral Controlled-Release 5-Fluorocytosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1237-1241.	1.4	17
125	Estimating the Glomerular Filtration Rate in Obese Adult Patients for Drug Dosing. <i>Advances in Chronic Kidney Disease</i> , 2010, 17, e53-e62.	0.6	115
126	Antifungal Combinations against Simulated <i>Candida albicans</i> Endocardial Vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2629-2631.	1.4	13

#	ARTICLE	IF	CITATIONS
127	Characterization of BBB Permeability in a Preclinical Model of Cryptococcal Meningoencephalitis Using Magnetic Resonance Imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 545-553.	2.4	13
128	Estimation of creatinine clearance in morbidly obese patients. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 642-648.	0.5	148
129	Activities and Ultrastructural Effects of Antifungal Combinations against Simulated <i>Candida</i> Endocardial Vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2367-2376.	1.4	24
130	Influence of Morbid Obesity on the Single-Dose Pharmacokinetics of Daptomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2741-2747.	1.4	86
131	Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 35-39.	1.4	144
132	Micafungin activity against <i>Candida</i> bloodstream isolates: effect of growth medium and susceptibility testing method. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 129-132.	0.8	13
133	High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. <i>Current Medical Research and Opinion</i> , 2007, 23, 1057-1065.	0.9	14
134	Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 557-562.	1.1	29
135	Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 919-927.	0.9	60
136	Antimicrobial Dosing Considerations in Obese Adult Patients. <i>Pharmacotherapy</i> , 2007, 27, 1081-1091.	1.2	222
137	Optimizing Antimicrobial Therapy for Gram-Positive Bloodstream Infections in Patients on Hemodialysis. <i>Advances in Chronic Kidney Disease</i> , 2006, 13, 259-270.	0.6	11
138	Antibiotic Drug Interactions. <i>Medical Clinics of North America</i> , 2006, 90, 1223-1255.	1.1	58
139	Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. <i>Journal of Cystic Fibrosis</i> , 2006, 5, 153-157.	0.3	44
140	Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi-Institutional Study. <i>Clinical Infectious Diseases</i> , 2006, 43, 25-31.	2.9	1,026
141	Non-Transferrin-Bound Iron Is Associated with Enhanced <i>Staphylococcus aureus</i> Growth in Hemodialysis Patients Receiving Intravenous Iron Sucrose. <i>American Journal of Nephrology</i> , 2006, 26, 304-309.	1.4	36
142	Epidemiology of Vancomycin-Induced Neutropenia In Patients Receiving Home Intravenous Infusion Therapy. <i>Annals of Pharmacotherapy</i> , 2006, 40, 224-228.	0.9	49
143	Using Vancomycin Concentrations for Dosing Daptomycin in a Morbidly Obese Patient with Renal Insufficiency. <i>Annals of Pharmacotherapy</i> , 2006, 40, 553-558.	0.9	7
144	Assessment of Effective Renal Plasma Flow, Enzymuria, and Cytokine Release in Healthy Volunteers Receiving a Single Dose of Amphotericin B Desoxycholate. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3784-3788.	1.4	25

#	ARTICLE	IF	CITATIONS
145	Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 1812-1816.	0.5	42
146	Extended-Interval Aminoglycoside Dosing for Treatment of Enterococcal and Staphylococcal Osteomyelitis. <i>Annals of Pharmacotherapy</i> , 2004, 38, 936-941.	0.9	9
147	Altered Susceptibility of <i>Candida glabrata</i> Bloodstream Isolates to Triazoles at Clinically Relevant pH Values: Comparison of the NCCLS M27-A2, Sensititre YeastOne, and Etest Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4441-4443.	1.4	7
148	Adjunctive Granulocyte Colony-Stimulating Factor Therapy for Diabetic Foot Infections. <i>Annals of Pharmacotherapy</i> , 2004, 38, 2150-2153.	0.9	6
149	Pharmacy Education: Beyond the Basics. <i>Pharmacotherapy</i> , 2004, 24, 690-693.	1.2	1
150	Voriconazole Inhibition of Tacrolimus Metabolism. <i>Clinical Infectious Diseases</i> , 2003, 36, 1089-1091.	2.9	37
151	Antifungal Susceptibility Testing in Teaching Hospitals. <i>Annals of Pharmacotherapy</i> , 2003, 37, 192-196.	0.9	3
152	Antifungal Susceptibility Testing in Teaching Hospitals. <i>Annals of Pharmacotherapy</i> , 2003, 37, 192-196.	0.9	10
153	Management of Candidiasis in Critically Ill Patients. <i>Journal of Pharmacy Practice</i> , 2002, 15, 106-113.	0.5	0
154	Risk Factors Associated with the Development of Infection with Linezolid and Vancomycin-Resistant <i>Enterococcus faecium</i> . <i>Clinical Infectious Diseases</i> , 2002, 35, 1269-1272.	2.9	114
155	Efficacy and Tolerability of Extended-Interval Aminoglycoside Administration in Pediatric Patients. <i>Paediatric Drugs</i> , 2002, 4, 469-484.	1.3	19
156	Plasma Pharmacokinetics and Tissue Penetration of Alatrofloxacin in Morbidly Obese Individuals. <i>Clinical Drug Investigation</i> , 2001, 21, 219-224.	1.1	6
157	Antimicrobial-Coated/Bonded and -Impregnated Intravascular Catheters. <i>Annals of Pharmacotherapy</i> , 2001, 35, 1255-1263.	0.9	66
158	Waste Generation of Drug Product Samples versus Prescriptions Obtained Through Pharmacy Dispensing. <i>Pharmacotherapy</i> , 2000, 20, 593-595.	1.2	8
159	Macrolide Drug Interactions: An Update. <i>Annals of Pharmacotherapy</i> , 2000, 34, 495-513.	0.9	80
160	The Origin of the "Ideal" Body Weight Equations. <i>Annals of Pharmacotherapy</i> , 2000, 34, 1066-1069.	0.9	288